Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.

Further Reading

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

18 Oct 2013
Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

10 Oct 2013
AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

7 Oct 2013
FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

30 Sep 2013
Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

Psoriasis and the nervous system: an interview with Dr Nicole Ward, Case Western Reserve University

27 Sep 2013
FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

23 Sep 2013
Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

10 Sep 2013
Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

Baxter, Coherus Ink Biosimilar Collaboration Worth Up To $246M

3 Sep 2013
University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

University of Pennsylvania resident receives inaugural Dr. Mark G. Lebwohl Medical Dermatology Fellowship

9 Jul 2013
Nearly half a million dollars given to physicians working to cure psoriatic diseases

Nearly half a million dollars given to physicians working to cure psoriatic diseases

3 Jul 2013
Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

Celgene International Sàr presents PALACE 3 phase III results of apremilast in psoriatic arthritis at EULAR

15 Jun 2013
Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

14 Jun 2013
Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

14 Jun 2013
Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

13 Jun 2013
Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

13 Jun 2013
New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

13 Jun 2013
Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

Celgene announces positive results from first phase III study of apremilast in psoriatic arthritis

12 Jun 2013
Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

Six top scientists studying psoriasis receive NPF research grants to discover new treatments for chronic diseases

5 Jun 2013
Synthetic compound derived from sea anemone toxin shows potential to treat obesity

Synthetic compound derived from sea anemone toxin shows potential to treat obesity

28 May 2013
Simponi injection gets FDA approval to treat adults with ulcerative colitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

16 May 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback